tiprankstipranks
Hikma Pharmaceuticals PLC (HKMPF)
OTHER OTC:HKMPF
US Market
HKMPF
Hikma Pharmaceuticals
RESEARCH TOOLSreports

Hikma Pharmaceuticals (HKMPF) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HKMPF Analyst Ratings

Moderate Buy
5Ratings
Moderate Buy
4 Buy
0 Hold
1 Sell
Based on 5 analysts giving stock ratings to
Hikma
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HKMPF Stock 12 Month Forecast

Average Price Target

$25.34
▲(19.25% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is $25.34 with a high forecast of $28.63 and a low forecast of $18.40. The average price target represents a 19.25% change from the last price of $21.25.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","22":"$22","29":"$29","18.5":"$18.5","25.5":"$25.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.625751,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.34060529,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.4022685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,18.5,22,25.5,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.079,21.659519307692307,22.240038615384616,22.820557923076922,23.401077230769232,23.981596538461538,24.562115846153848,25.142635153846154,25.723154461538464,26.30367376923077,26.88419307692308,27.464712384615385,28.045231692307695,{"y":28.625751,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.079,21.406815791538463,21.734631583076922,22.062447374615385,22.390263166153847,22.718078957692306,23.04589474923077,23.37371054076923,23.701526332307694,24.029342123846153,24.357157915384615,24.684973706923074,25.012789498461537,{"y":25.34060529,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.079,20.873097576923076,20.667195153846155,20.46129273076923,20.25539030769231,20.049487884615385,19.843585461538463,19.63768303846154,19.431780615384618,19.225878192307693,19.019975769230772,18.814073346153847,18.608170923076926,{"y":18.4022685,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.113,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.451,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.185,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.861,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.904,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.406,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.117,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.956,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.583,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.177,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.91,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.079,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.63Average Price Target$25.34Lowest Price Target$18.40
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on HKMPF
James Vane
Jefferies
Jefferies
$27.6
Buy
29.90%
Upside
Reiterated
08/25/26
Jefferies Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)
Citi Analyst forecast on HKMPF
Giang Nguyen
Citi
Citi
$23.17→$25.49
Buy
19.96%
Upside
Reiterated
08/12/26
Citi Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)
Berenberg Bank Analyst forecast on HKMPF
Beatrice Fairbairn
Berenberg Bank
Berenberg Bank
$24.54→$28.63
Buy
34.71%
Upside
Reiterated
08/11/26
Hikma Pharmaceuticals (HIK) Gets a Buy from Berenberg Bank
Deutsche Bank Analyst forecast on HKMPF
Kane Slutzkin
Deutsche Bank
Deutsche Bank
$26.58
Buy
25.09%
Upside
Reiterated
08/07/26
Deutsche Bank Remains a Buy on Hikma Pharmaceuticals (HIK)
Barclays Analyst forecast on HKMPF
James Gordon CFA
Barclays
Barclays
$18.4
Sell
-13.40%
Downside
Reiterated
06/23/26
Barclays Sticks to Their Sell Rating for Hikma Pharmaceuticals (HIK)
J.P. Morgan Analyst forecast on HKMPF
Zain Ebrahim
J.P. Morgan
J.P. Morgan
$27.26
Buy
28.29%
Upside
Reiterated
03/03/26
Hikma Pharmaceuticals (HIK) Receives a Buy from J.P. Morgan
Peel Hunt Analyst forecast on HKMPF
Unknown Analyst
Peel Hunt
Not Ranked
Peel Hunt
$29.58
Buy
39.20%
Upside
Reiterated
11/07/25
Peel Hunt Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on HKMPF
James Vane
Jefferies
Jefferies
$27.6
Buy
29.90%
Upside
Reiterated
08/25/26
Jefferies Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)
Citi Analyst forecast on HKMPF
Giang Nguyen
Citi
Citi
$23.17→$25.49
Buy
19.96%
Upside
Reiterated
08/12/26
Citi Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)
Berenberg Bank Analyst forecast on HKMPF
Beatrice Fairbairn
Berenberg Bank
Berenberg Bank
$24.54→$28.63
Buy
34.71%
Upside
Reiterated
08/11/26
Hikma Pharmaceuticals (HIK) Gets a Buy from Berenberg Bank
Deutsche Bank Analyst forecast on HKMPF
Kane Slutzkin
Deutsche Bank
Deutsche Bank
$26.58
Buy
25.09%
Upside
Reiterated
08/07/26
Deutsche Bank Remains a Buy on Hikma Pharmaceuticals (HIK)
Barclays Analyst forecast on HKMPF
James Gordon CFA
Barclays
Barclays
$18.4
Sell
-13.40%
Downside
Reiterated
06/23/26
Barclays Sticks to Their Sell Rating for Hikma Pharmaceuticals (HIK)
J.P. Morgan Analyst forecast on HKMPF
Zain Ebrahim
J.P. Morgan
J.P. Morgan
$27.26
Buy
28.29%
Upside
Reiterated
03/03/26
Hikma Pharmaceuticals (HIK) Receives a Buy from J.P. Morgan
Peel Hunt Analyst forecast on HKMPF
Unknown Analyst
Peel Hunt
Not Ranked
Peel Hunt
$29.58
Buy
39.20%
Upside
Reiterated
11/07/25
Peel Hunt Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hikma Pharmaceuticals

3 Months
Beatrice FairbairnBerenberg Bank
Success Rate
4/4 ratings generated profit
100%
Average Return
+9.53%
Copying Beatrice Fairbairn's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +9.53% per trade.
1 Year
Beatrice FairbairnBerenberg Bank
Success Rate
4/4 ratings generated profit
100%
Average Return
+17.32%
Copying Beatrice Fairbairn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +17.32% per trade.
2 Years
Beatrice FairbairnBerenberg Bank
Success Rate
4/4 ratings generated profit
100%
Average Return
+17.32%
Copying Beatrice Fairbairn's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +17.32% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HKMPF Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
1
0
0
0
Buy
2
3
3
3
6
Hold
0
0
0
0
0
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
4
5
4
4
7
In the current month, HKMPF has received 6 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. HKMPF average Analyst price target in the past 3 months is 25.34.
Each month's total comprises the sum of three months' worth of ratings.

HKMPF Financial Forecast

HKMPF Earnings Forecast

Next quarter’s earnings estimate for HKMPF is $1.13 with a range of $1.13 to $1.13. The previous quarter’s EPS was $1.26. HKMPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HKMPF has Performed in-line its overall industry.
Next quarter’s earnings estimate for HKMPF is $1.13 with a range of $1.13 to $1.13. The previous quarter’s EPS was $1.26. HKMPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HKMPF has Performed in-line its overall industry.

HKMPF Sales Forecast

Next quarter’s sales forecast for HKMPF is $1.75B with a range of $1.75B to $1.75B. The previous quarter’s sales results were $1.73B. HKMPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HKMPF has Performed in-line its overall industry.
Next quarter’s sales forecast for HKMPF is $1.75B with a range of $1.75B to $1.75B. The previous quarter’s sales results were $1.73B. HKMPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HKMPF has Performed in-line its overall industry.

HKMPF Stock Forecast FAQ

What is HKMPF’s average 12-month price target, according to analysts?
Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 25.34.
    What is HKMPF’s upside potential, based on the analysts’ average price target?
    Hikma Pharmaceuticals PLC has 19.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HKMPF a Buy, Sell or Hold?
          Hikma Pharmaceuticals PLC has a consensus rating of Moderate Buy which is based on 4 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Hikma Pharmaceuticals PLC’s price target?
            The average price target for Hikma Pharmaceuticals PLC is 25.34. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $28.63 ,the lowest forecast is $18.40. The average price target represents 19.25% Increase from the current price of $21.25.
              What do analysts say about Hikma Pharmaceuticals PLC?
              Hikma Pharmaceuticals PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of HKMPF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.